• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

L’Oréal buys Medik8, expanding its portfolio in anti-aging skincare market

by June 9, 2025
by June 9, 2025

French cosmetics behemoth L’Oréal is set to acquire Medik8, a British skincare brand renowned for its vitamin A-based anti-aging products.

The deal, announced Monday by Medik8’s current owner, UK-based private equity firm Inflexion, marks another strategic move by L’Oréal to deepen its presence in the rapidly expanding and highly lucrative dermatological skincare market.

While the financial terms of the acquisition were not disclosed, the addition of Medik8 is poised to enhance L’Oréal’s already formidable dermatological beauty division.

This unit, which boasts powerhouse brands such as CeraVe, La Roche-Posay, and SkinCeuticals, has been L’Oréal’s fastest-growing segment in recent years.

It achieved impressive revenues of 7 billion euros ($7.99 billion) last year, following nearly 10% growth from the year prior.

This division is also notable for having the highest profit margin among L’Oréal’s four main business units.

The surge in consumer interest for science-backed skincare products has been a primary driver of this division’s success.

However, growth in this popular category has recently shown signs of moderation due to intensifying competition from both established players and emerging niche brands.

Strategic acquisition drive: reviving growth and expanding reach

L’Oréal executives have openly stated this year that the company is actively pursuing acquisitions as a strategy to revive flagging growth in certain areas and to further expand its global footprint.

The Medik8 purchase aligns perfectly with this objective.

This latest acquisition follows L’Oréal’s move in December to buy Korean skincare brand Dr.G and its acquisition of a minority stake in Oman-based luxury perfume house Amouage last year, signaling a consistent appetite for strategic additions to its portfolio.

Inflexion, the private equity firm selling Medik8, will retain a minority shareholding in the brand as part of the transaction.

According to a statement from Inflexion, “The partnership with L’Oreal will allow Medik8 to deepen its presence in existing markets and expand globally.”

This suggests a collaborative approach to nurturing Medik8’s future growth under L’Oréal’s ownership, leveraging the French giant’s extensive global distribution network and marketing prowess.

The post L’Oréal buys Medik8, expanding its portfolio in anti-aging skincare market appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Is full self-driving real or just hype? Promise, progress, and what’s on the road
next post
Europe markets open: stocks dip ahead of key US-China meeting; Chinese trade data disappoints

Related Posts

Takaichi trade sparks Nikkei 225 Index bull run...

January 14, 2026

Silver tops $90/oz on rate-cut bets, geopolitical tensions;...

January 14, 2026

Morning brief: Asian stocks rise on Japan election...

January 14, 2026

Coca-Cola drops Costa Coffee sale after private equity...

January 14, 2026

Germany’s second-largest bank, DZ Bank, approves Bitcoin and...

January 14, 2026

China’s Zhipu trains AI image model on Huawei...

January 14, 2026

Saudi PIF shifts $12B gaming stakes to Savvy...

January 14, 2026

Lloyds share price rally accelerates — will this...

January 14, 2026

Nigeria set to introduce AI rules to rein...

January 13, 2026

SK Hynix to ramp up advanced chip packaging...

January 13, 2026

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • AIER’s Everyday Price Index Levels Off in December 2025

    January 14, 2026
  • The Powell Affair and the Limits of The Fed’s Immunity

    January 14, 2026
  • China’s Rare Earth ‘Monopoly’ — and Why Markets Will Break It

    January 14, 2026
  • Takaichi trade sparks Nikkei 225 Index bull run and Japanese yen crash

    January 14, 2026
  • Silver tops $90/oz on rate-cut bets, geopolitical tensions; is $100 next?

    January 14, 2026
  • Morning brief: Asian stocks rise on Japan election bets; Silver, BTC hit highs

    January 14, 2026

Editors’ Picks

  • 1

    Pop Mart reports 188% profit surge, plans aggressive global expansion

    March 26, 2025
  • 2

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 5

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 6

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025
  • 7

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025

Categories

  • Economy (3,802)
  • Editor's Pick (404)
  • Investing (378)
  • Stock (2,553)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

NatWest share price forecast as its earnings...

October 24, 2025

Eli Lilly seen as the stronger bet...

June 26, 2025

Standard General approached by WBD shareholders for...

December 18, 2025